AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31375516 — intervention group
Group type: EXPERIMENTAL
Intervention: UPD on chromosome arm 11p
Number of subjects: 109
Study 31375516 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of UPDs of 13q and 11p
Number of subjects: 109
Study 31375618 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective multicentre observational biobank, databank and imagebank of patients with AAA
Number of subjects: 0
Study 31375618 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomaterials collected include blood (including DNA and RNA), urine, and AAA tissue if open surgical repair is performed.
Number of subjects: 0
Study 31375618 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging data obtained as part of clinical care stored in the imagebank.
Number of subjects: 0
Study 31375837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg)
Number of subjects: 1554
Study 31375837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 1554
Study 31375837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1554
Study 31376032 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 145
Study 31376090 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264
Study 31376090 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14264
Study 31376090 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and Warfarin
Number of subjects: 14264
Study 31376493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virologic response (SVR)
Number of subjects: 4476
Study 31376493 — intervention group
Group type: COMPARATOR
Intervention: No sustained virologic response (non-SVR)
Number of subjects: 4476
Study 31376871 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 584
Study 31376871 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 584
Study 31376871 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight
Number of subjects: 584
Study 31376874 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 308
Study 31377111 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery programme (ERP)
Number of subjects: 302
Study 31377161 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypofractionation (MH-RT; 26 fractions of 2.7 Gy to a total dose of 70.2 Gy)
Number of subjects: 421
Study 31377161 — intervention group
Group type: COMPARATOR
Intervention: Extreme hypofractionation (EH-RT; fractions of 6.5-7 Gy to a total dose of 32.5-35 Gy)
Number of subjects: 421
Study 31377265 — intervention group
Group type: EXPERIMENTAL
Intervention: Triac (350 μg initial dose, escalating in 350 μg increments)
Number of subjects: 46
Study 31377265 — intervention group
Group type: EXPERIMENTAL
Intervention: Triac (mean dose of 38.3 μg/kg, range 6.4-84.3 μg/kg)
Number of subjects: 46
Study 31377502 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater relationship satisfaction
Number of subjects: 150
Study 31377502 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship satisfaction
Number of subjects: 150
Study 31377502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate variables (depression, communication satisfaction)
Number of subjects: 150
Study 31377694 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiotherapy (SBRT) with doses of 5×6, 6×6, or 5×5 Gy
Number of subjects: 47
Study 31377694 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiotherapy (SBRT)
Number of subjects: 47
Study 31377712 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial model of resilience interventions tailored to young patients' specific needs
Number of subjects: 0
Study 31377712 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires assessing psychological distress, coping strategies, QoL, psychological well-being, and resilience
Number of subjects: 0
Study 31377771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopy
Number of subjects: 264
Study 31377771 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopy
Number of subjects: 264
Study 31377771 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 264
Study 31377771 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laparoscopy
Number of subjects: 264
Study 31377849 — intervention group
Group type: EXPERIMENTAL
Intervention: Canaloplasty combined with phacoemulsification
Number of subjects: 15
Study 31377946 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV4 + Tdap + MenACWY
Number of subjects: 801
Study 31377946 — intervention group
Group type: COMPARATOR
Intervention: HPV4 + Tdap + Placebo
Number of subjects: 801
Study 31378080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (6-week group mindfulness intervention)
Number of subjects: 26
Study 31378084 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapies (ADTs)
Number of subjects: 6560565
Study 31378084 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide and other ADTs
Number of subjects: 6560565
Study 31378102 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of tubule biomarkers into prognostic scores
Number of subjects: 0
Study 31378102 — intervention group
Group type: COMPARATOR
Intervention: Clinical kidney measures (eGFR and albuminuria)
Number of subjects: 0
Study 31378427 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable Organ Care System (OCS) Lung perfusion and ventilation
Number of subjects: 93
Study 31378459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks plus pamiparib 40 mg twice daily (recommended phase 2 dose)
Number of subjects: 49
Study 31378459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib with tislelizumab
Number of subjects: 49
Study 31378656 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 3155
Study 31378656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 3155
Study 31378693 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational Infrastructure Paediatric Plan (OIPP)
Number of subjects: 1636
Study 31378695 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-gene assay (CXCL10, FCGR1A, FCGR1B, GBP1, GBP4, IL15, KLRC1, TIMP1)
Number of subjects: 387
Study 31378695 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-gene assay
Number of subjects: 387
Study 31379605 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic endurance training (2-week, twice daily)
Number of subjects: 89
Study 31379605 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercise training (2-week, twice daily)
Number of subjects: 89
Study 31379605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 31379673 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy (CFT)
Number of subjects: 0
Study 31379673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 0
Study 31379701 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon Beta 1b
Number of subjects: 0
Study 31379701 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31379715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tractography-based grading scale for AVMs
Number of subjects: 0
Study 31379734 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Pasireotide
Number of subjects: 0
Study 31380382 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Microbial-Based Immunotherapy
Number of subjects: 0
Study 31380561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (high score)
Number of subjects: 67332
Study 31380687 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 782
Study 31381524 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-DBS
Number of subjects: 0
Study 31381524 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIHEP3
Number of subjects: 0
Study 31381526 — intervention group
Group type: EXPERIMENTAL
Intervention: AVXS-101 (onasemnogene abeparvovec)
Number of subjects: 12
Study 31381526 — intervention group
Group type: COMPARATOR
Intervention: Natural history cohort (NN101)
Number of subjects: 12
Study 31381880 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-point LUS method (two bilateral positive points)
Number of subjects: 117
Study 31381880 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-point LUS method
Number of subjects: 117
Study 31381880 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-point LUS method (≥ 1 bilateral positive point)
Number of subjects: 117
Study 31381880 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-point LUS method (B-line count ≥ 30)
Number of subjects: 117
Study 31382020 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab therapy (mean dosage 473 mg every 4 weeks, mean duration 2.49 years)
Number of subjects: 198
Study 31382765 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired serial positron emission tomography-coronary computed tomography angiography imaging
Number of subjects: 30
Study 31382880 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty and complexity computation algorithms derived from the interRAI-HC assessments.
Number of subjects: 3
Study 31382880 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment protocols for use by homecare nurses.
Number of subjects: 3
Study 31382880 — intervention group
Group type: COMPARATOR
Intervention: InterRAI-HC assessments at three measurement occasions.
Number of subjects: 3
Study 31382942 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin educational video delivered on an electronic tablet (iPad)
Number of subjects: 18
Study 31383691 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section (CS)
Number of subjects: 39026
Study 31383691 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 39026
Study 31383691 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged and obstructed labour as the reason for CS
Number of subjects: 39026
Study 31383812 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and etoposide (oral etoposide at 50 mg/day on days 1-14 and intravenous irinotecan at 100 mg/m2)
Number of subjects: 31
Study 31383903 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail participants
Number of subjects: 170
Study 31383903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-frail participants
Number of subjects: 170
Study 31383903 — intervention group
Group type: COMPARATOR
Intervention: Frail and pre-frail participants
Number of subjects: 170
Study 31384309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (80 mg/day) for 1 year
Number of subjects: 141
Study 31384309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (dose escalations in 3-week intervals)
Number of subjects: 141
Study 31384309 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 141
Study 31384310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 98
Study 31384310 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide 5 mg/day
Number of subjects: 98
Study 31384312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with docetaxel and cyclophosphamide (75/600 mg/m2) for four 3-weekly cycles
Number of subjects: 106
Study 31384312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with docetaxel and cyclophosphamide
Number of subjects: 106
Study 31384956 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthyroid Graves' disease patients
Number of subjects: 62
Study 31384956 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 62
Study 31384986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/daclatasvir with ribavirin
Number of subjects: 67
Study 31384986 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir/daclatasvir without ribavirin
Number of subjects: 67
Study 31385109 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-endothelin B receptor antibody-drug conjugate DEDN6526A; specific dosage and duration not mentioned.
Number of subjects: 0
Study 31385109 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details on control treatment not available.
Number of subjects: 0
Study 31385163 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 774
Study 31385163 — intervention group
Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 774
Study 31385389 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard course of systemic corticosteroid and antibiotic treatment
Number of subjects: 346
Study 31385389 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil count <0.144 × 10^9/L
Number of subjects: 346
Study 31385428 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-derived AECOPD episodes
Number of subjects: 2269
Study 31385428 — intervention group
Group type: EXPERIMENTAL
Intervention: eCRF-derived moderate/severe AECOPD episodes
Number of subjects: 2269
Study 31385427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin stents
Number of subjects: 843
Study 31385427 — intervention group
Group type: COMPARATOR
Intervention: PF-BESs
Number of subjects: 843
Study 31385427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin stents (in ULM group)
Number of subjects: 843
Study 31385427 — intervention group
Group type: COMPARATOR
Intervention: PF-BESs (in ULM group)
Number of subjects: 843
Study 31385427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin stents (in non-ULM group)
Number of subjects: 843
Study 31385427 — intervention group
Group type: COMPARATOR
Intervention: PF-BESs (in non-ULM group)
Number of subjects: 843
Study 31385427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin stents (two-stent strategy)
Number of subjects: 843
Study 31385427 — intervention group
Group type: COMPARATOR
Intervention: PF-BESs (two-stent strategy)
Number of subjects: 843
Study 31385427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin stents (1 month DAPT)
Number of subjects: 843
Study 31385427 — intervention group
Group type: COMPARATOR
Intervention: PF-BESs (1 month DAPT)
Number of subjects: 843
Study 31385617 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (400 mg twice daily for 8 days)
Number of subjects: 18
Study 31386042 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic yoga (DY) intervention
Number of subjects: 20
Study 31386042 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC) group
Number of subjects: 20
Study 31386061 — intervention group
Group type: EXPERIMENTAL
Intervention: Central review of cognitive test scoring
Number of subjects: 500
Study 31386061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopkins Verbal Learning Test-Revised
Number of subjects: 500
Study 31386061 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Oral Word Association
Number of subjects: 500
Study 31386061 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test-A
Number of subjects: 500
Study 31386061 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test-B
Number of subjects: 500
Study 31386061 — intervention group
Group type: COMPARATOR
Intervention: Onsite electronic data entry without central review
Number of subjects: 500
Study 31386157 — intervention group
Group type: COMPARATOR
Intervention: Dietary pattern high in soy, vegetables, fruits, tea, tomato products, bread, fish, margarine, and dairy; low in rice, red meat, coffee, alcohol, sugar-sweetened beverages, and eggs.
Number of subjects: 711
Study 31386611 — intervention group
Group type: EXPERIMENTAL
Intervention: Response- and biology-based therapy
Number of subjects: 404
Study 31387539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgG assay
Number of subjects: 202
Study 31387539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgA assay
Number of subjects: 202
Study 31387539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgM assay
Number of subjects: 202
Study 31387539 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactomannan (GM) test
Number of subjects: 202
Study 31387539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgG, IgA, IgM assays and GM test cut-off values
Number of subjects: 202
Study 31387577 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity interventions
Number of subjects: 693
Study 31387577 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection from medical staff
Number of subjects: 693
Study 31387577 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative data collection at diagnosis, 6 months, and 1 year
Number of subjects: 693
Study 31387577 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective study of societal and policy factors
Number of subjects: 693
Study 31387885 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and cetuximab
Number of subjects: 65
Study 31388343 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding experience of mothers of preterm infants
Number of subjects: 270
Study 31388454 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8232 40 mg monotherapy
Number of subjects: 0
Study 31388454 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8232 40 mg and monthly intravitreal ranibizumab 0.3 mg combination therapy
Number of subjects: 0
Study 31388454 — intervention group
Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.3 mg monotherapy
Number of subjects: 0
Study 31388598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) programme, 2-h class, once a week for 12 weeks
Number of subjects: 0
Study 31388598 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise programme (SEP) consisting solely of other IC patients
Number of subjects: 0
Study 31388661 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth clinical decision-making support intervention
Number of subjects: 65831
Study 31388661 — intervention group
Group type: COMPARATOR
Intervention: Control (no mHealth intervention)
Number of subjects: 65831
Study 31388703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metamizole (10 mg/kg)
Number of subjects: 25
Study 31389718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study 31390004 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal nerve branch density (CNBD) in patients with painful DSPN
Number of subjects: 162
Study 31390004 — intervention group
Group type: COMPARATOR
Intervention: Corneal nerve fiber density and corneal nerve fiber length in both DSPN types
Number of subjects: 162
Study 31390004 — intervention group
Group type: COMPARATOR
Intervention: Associations of corneal confocal microscopy (CCM) measures with nerve conduction (NC) and cold perception threshold
Number of subjects: 162
Study 31390128 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with vascular-related diseases (hypertension, diabetes, CAD, stroke, PAD)
Number of subjects: 13798
Study 31390128 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with each vascular-related disease
Number of subjects: 13798
Study 31390128 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with hypertension
Number of subjects: 13798
Study 31390128 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with vascular-related diseases after adjustment for hypertension
Number of subjects: 13798
Study 31390128 — intervention group
Group type: COMPARATOR
Intervention: Participants without vascular-related diseases
Number of subjects: 13798
Study 31390274 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-eribulin combination treatment
Number of subjects: 24
Study 31390282 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Portal Intervention
Number of subjects: 0
Study 31390282 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31390982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume challenge (V)
Number of subjects: 38
Study 31391005 — intervention group
Group type: EXPERIMENTAL
Intervention: Zika virus infection during pregnancy (symptomatic confirmed by ZIKV RNA and/or IgM)
Number of subjects: 10000
Study 31391045 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HOMA-IR levels
Number of subjects: 485
Study 31391045 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)
Number of subjects: 485
Study 31391045 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 485
Study 31391045 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR and IGT interaction
Number of subjects: 485
Study 31391177 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematopoietic stem cell transplantation (HSCT)
Number of subjects: 62
Study 31391177 — intervention group
Group type: COMPARATOR
Intervention: Monthly cyclophosphamide (CYC) treatment
Number of subjects: 62
Study 31391177 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT
Number of subjects: 62
Study 31391203 — intervention group
Group type: EXPERIMENTAL
Intervention: Four diabetes medications added to metformin
Number of subjects: 5047
Study 31391203 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 5047
Study 31391226 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab
Number of subjects: 0
Study 31391334 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib therapy
Number of subjects: 30
Study 31391862 — intervention group
Group type: EXPERIMENTAL
Intervention: C-117 formula
Number of subjects: 120
Study 31391862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31391947 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-medical psychosocial counselling (PSY)
Number of subjects: 287
Study 31391947 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 287
Study 31391949 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF 240 mg twice daily
Number of subjects: 0
Study 31391949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31392048 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide monotherapy
Number of subjects: 91